Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RSMDF) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Resmed (RSMDF) over the last 17 years, with Q4 2025 value amounting to $2.69.

  • Resmed's EPS (Basic) rose 1446.81% to $2.69 in Q4 2025 from the same period last year, while for Dec 2025 it was $10.15, marking a year-over-year increase of 1955.24%. This contributed to the annual value of $9.55 for FY2025, which is 3756.73% up from last year.
  • As of Q4 2025, Resmed's EPS (Basic) stood at $2.69, which was up 1446.81% from $2.38 recorded in Q3 2025.
  • Resmed's 5-year EPS (Basic) high stood at $2.69 for Q4 2025, and its period low was -$0.54 during Q1 2021.
  • Moreover, its 5-year median value for EPS (Basic) was $1.55 (2023), whereas its average is $1.69.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 14778.76% in 2021, then surged by 32592.59% in 2022.
  • Quarter analysis of 5 years shows Resmed's EPS (Basic) stood at $1.38 in 2021, then increased by 10.87% to $1.53 in 2022, then dropped by 7.19% to $1.42 in 2023, then skyrocketed by 65.49% to $2.35 in 2024, then increased by 14.47% to $2.69 in 2025.
  • Its last three reported values are $2.69 in Q4 2025, $2.38 for Q3 2025, and $2.59 during Q2 2025.